Selecta Biosciences (SELB) Receives a Buy from Stifel Nicolaus

By Ryan Adsit

In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Selecta Biosciences (SELBResearch Report), with a price target of $6.00. The company’s shares closed last Monday at $1.41, close to its 52-week low of $1.28.

According to TipRanks.com, Archila has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.8% and a 31.9% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Pacira Pharmaceuticals.

Selecta Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $6.33, representing a 295.6% upside. In a report released today, Needham also maintained a Buy rating on the stock with a $9.00 price target.

See today’s analyst top recommended stocks >>

Based on Selecta Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $16.39 million. In comparison, last year the company had a GAAP net loss of $16 million.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SELB in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.